Grant project highlights
Funding agencies
CD20 CAR-TIME
CD20 CAR transduced T cells for individualized melanoma therapy
Fkz 01EK1507A
ART4Fun
Antigen reactive T cells for diagnosis and therapy of fungus-associated diseases in high-risk patients
Fkz 03ZZ0813F
iCARE
Induced pluripotent stem cells for cellular therapy of cardiac diseases
Fkz 01EK1601D
iPStemRNA
Generation of GMP-compliant induced pluripotent stem cells from universal donors.
Sub-project: Development of prototypes and material for GMP-compliant production of iPS cells
Fkz 01EK1610C
ReSight
Generation of transplantable hiPSC-derived retinal cells for treatment of retinal degeneration
Fkz 01EK1613C
ELICIT
Advanced confocal light sheet microscopy for clinical high-throughput analysis of immune cell infiltration of tumor samples.
Sub-project: Development, verification and adaptation of specific probes for light sheet microscopy
Fkz 13N14347
T-FITNESS
Fine-tuning cell networks of exhaustion by synthetic sensors
GA101070740
PROCROP
Professional cross-priming for ovary and prostate cancer
GA 635122
SCIDNET
Developing Genetic medicines for Severe Combined Immunodeficiency
GA 666908
CARAT
Chimeric Antigen Receptors for Advanced Therapies
GA 667980
PIX4LIFE
Silicon Nitride Photonic Integrated Circuit Pilot line for Life Science Applications in the Visible Range
GA 688519
Trace
Transfer of multivirus-specific T-cells following transplantation
GA 755005
MATURE-NK
Manufacturing of Tumour-Reactive Natural Killer cells
GA 765104
EUROoC
Interdisciplinary training network for advancing Organ-on-a-chip technology in Europe
GA 812954
ENDONANO
Quantitative detection of bacterial endotoxin by novel nanotechnological approaches
GA 812661
Mecklenburg-West Pomerania
PiCoP
Peptide-based immunization strategies for Colon and Pancreas carcinomas
TBI-V-1-243-VBU-085
MACS-MS
Analysis of biomarkers for the detection of apheresis responders and glucocorticosteroid responders in multiple sclerosis patients with acute disease relapse
TBI-V-1-269-VBU-095
North Rhine Westfalia
iCAN33
Development of an immunotherapy for acute myeloid leukaemias (AMLs) using allogeneic natural killer (NK) cells with CD33 CARs
LS-2-1-018g
ImmunePredict
Development of new predictive markers for response to immune checkpoint inhibitors of solid tumors
LS-2-1-002b
TraCAR
Non-invasive imaging of pharmacokinetics and optimisation of CAR T-cell therapies of solid tumours
LS-2-2-050a
CardioPatch
Vascularised, bioartificial heart muscle from induced pluripotent stem cells
LS-2-2-029f
